Biocon Ltd (BIOCON)
🎯 Key Takeaways
- Biocon is in a strategic transition phase, shifting from a services-dependent model toward biosimilars and generics as primary growth drivers, with recent financials showing mixed performance but strong underlying momentum in high-margin segments. While net profit declined in Q1 FY27 due to exceptional items and services weakness, biosimilars growth and margin expansion signal a foundational shift in revenue composition and operational focus.
- Revenue declined 4% QoQ to ₹4,336 in Q1FY27.
- ⚠️ 1) Persistent weakness in services revenue, which declined 16% YoY in Q1 FY27 and remains a drag on overall growth. 2) Reliance on biosimilars for fut
- Market Cap
- ₹61,114
- P/E Ratio
- 146.5
- P/B Ratio
- 1.79
- ROE
- 1.4%
- ROCE
- 2.9%
- Debt/Equity
- 0.43
- Div Yield
- 0.13%
- Promoter
- 44.7%
📖 The Story
Biocon is in a strategic transition phase, shifting from a services-dependent model toward biosimilars and generics as primary growth drivers, with recent financials showing mixed performance but strong underlying momentum in high-margin segments. While net profit declined in Q1 FY27 due to exceptional items and services weakness, biosimilars growth and margin expansion signal a foundational shift in revenue composition and operational focus.
📰 What's Happening
In Q1 FY27, biosimilars revenue grew 16% YoY to ₹2,855 crores, driven by North American launches and EMA approval for a Malaysia fill-finish plant, while generics EBITDA margin expanded by 250 bps to 21%. Despite a 4% YoY revenue decline and 12% drop in net profit, management highlighted strong biosimilars momentum and expects H2 FY27 performance to improve, with growth anticipated to accelerate through the year.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 4,296 | 4,173 | 4,517 | 4,336 |
| Operating Profit | 362 | 318 | 507 | 300 |
| OPM % | 8.4% | 7.6% | 11.2% | 6.9% |
| Net Profit | 133 | -52 | 199 | 137 |
| EPS | ₹0.66 | ₹1.08 | ₹0.79 | ₹0.87 |
Revenue has shown volatility over the past four quarters, peaking at ₹4,517 crores in Mar 2026 before declining to ₹4,336 crores in Jun 2026, with net profit turning negative in Dec 2025 before recovering to ₹137 crores in Jun 2026. This pattern reflects a services headwind offsetting gains in biosimilars and generics, but margin expansion in core segments suggests improving operational efficiency despite top-line pressure.
🔮 Management Outlook & What's Next
Management expects H2 FY27 to deliver improved performance, citing sustained biosimilars momentum, EMA approvals, and the transition of services into a recovery phase. They emphasize long-term growth through strategic acquisitions and capital allocation discipline, with no specific revenue or margin targets provided but confidence in second-half acceleration.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 600 | 600 | 811 | 669 |
| Reserves | 21,044 | 20,393 | 33,329 | 26,135 |
| Borrowings | 18,362 | 16,771 | 14,825 | 16,536 |
| Total Liabilities | 58,797 | 57,128 | 63,651 | 62,760 |
| Fixed Assets | 9,312 | 8,099 | 38,860 | 9,476 |
| Investments | 1,127 | 1,809 | 1,779 | 2,333 |
| Total Assets | 58,797 | 57,128 | 63,651 | 62,760 |
Equity has grown steadily from ₹600 crores in Mar 2025 to ₹811 crores in Mar 2026, while borrowings have declined from ₹18,362 crores to ₹14,825 crores, indicating active deleveraging. Reserves have increased significantly, reflecting capital efficiency and retained earnings, supporting a stronger capital structure amid strategic investments in biosimilars and global expansion.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +1,994 |
| Investing | -2,082 |
| Financing | -924 |
| Net Cash Flow | -1,012 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 54.5% | 44.9% | 44.7% |
| FII | 7.4% | 7.5% | 8.1% |
| DII | 21.7% | 24.1% | 23.4% |
| Public | 12.4% | 10.0% | 10.3% |
| # Shareholders | 3,94,279 | 3,86,593 | 3,92,833 |
Promoter holding has declined from 54.45% in Q3FY26 to 44.68% in Q1FY27, while FII and DII ownership have increased to 8.14% and 23.39% respectively, suggesting institutional confidence despite promoter reduction. The rising number of shareholders (3,92,833) and stable institutional inflows reflect broadening confidence, though the drop in promoter stake warrants monitoring for strategic intent.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent weakness in services revenue, which declined 16% YoY in Q1 FY27 and remains a drag on overall growth. 2) Reliance on biosimilars for future momentum, with no guarantee of sustained U.S. or international launch success amid intense competition. 3) Margin improvement in generics may be offset by pricing pressure or regulatory delays in key markets like the U.S.
📋 Recent Filings
- Announcement2026-09-25Biocon announced that its Malaysian subsidiary obtained MHRA approval for a new insulin fill-finish unit, building on prior EMA clearance secured in J…
- 🔴 Announcement2026-09-21Biocon announced that its biosimilar Pertuzumab received a positive EMA CHMP recommendation for treating HER2-positive breast cancer under the brand n…
- 🔴 Corporate Action2026-09-09Biocon announced a final dividend of ₹0.50 per share for FY 2025-26, approved at the August 6, 2026 AGM, with electronic remittance to eligible shareh…
- 🔴 Announcement2026-09-08Biocon announced its upcoming investor meetings schedule, including a Sep 11 roadshow in Mumbai, to engage analysts and institutional investors. The c…
- 🔴 Announcement2026-09-08Biocon announced a 10-year supply agreement for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis, securing exclusive access to …
- 🔴 Announcement2026-08-31Biocon announced its schedule of analyst and institutional investor meetings for September 4, 2026, including a virtual session with Nomura Asian Cred…
- 🔴 Corporate Action2026-08-28Biocon announced a final dividend of ₹0.50 per share for FY 2025-26, approved at the August 6, 2026 AGM, with electronic remittance to shareholders on…
- Announcement2026-08-25Biocon announced that its subsidiary Biocon Biologics received marketing approval from Japan's MHLW for a pegfilgrastim biosimilar, enabling sales in …
- Announcement2026-08-18Biocon announced that its U.S. subsidiary received FDA supplemental approval for Yesintek® prefilled autoinjectors in two strengths, expanding treatme…
- Announcement2026-08-11Biocon announced its management will meet analysts and institutional investors on August 17, 2026, at the Motilal Oswal 22nd Annual Global Investor Co…
🧠 Analyst's Read
Biocon is undergoing a structural shift toward biosimilars and global generics, with improving margins and capital discipline, but near-term profitability is being pressured by services decline and macroeconomic headwinds. The next few quarters will be critical to validate sustained growth in high-margin segments and whether the services recovery materializes as expected.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BIOCON files new disclosures
Track BIOCON filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BIOCON — FreeFree account · 2 AI queries/day